NMDA receptors and the l-arginine-nitric oxide-cyclic guanosine monophosphate pathway are implicated in the antidepressant-like action of the ethanolic extract from tabebuia avellanedae in mice

Journal of Medicinal Food

Volumn 16, Issue 11, 2013, Pages 1030-1038

  Freitas, Andiara E ^a   Moretti, Morgana ^a   Budni, Josiane ^a   Balen, Grasiela O ^a   Fernandes, Sinara C ^a   Veronezi, Patricia O ^a   Heller, Melina ^a   Micke, Gustavo A ^a   Pizzolatti, Moacir G ^a   Rodrigues, Ana Lúcia S ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Depression; L arginine nitric oxide cGMP pathway; NMDA receptors; Tabebuia avellanedae; Tail suspension test

Indexed keywords

1H [1,2,4]OXADIAZOLE[4,3 A]QUINOXALIN 1 ONE; 7 NITROINDAZOLE; ALCOHOL; ANTIDEPRESSANT AGENT; ARGININE; CYCLIC GMP; DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITRIC OXIDE; PLANT EXTRACT; SILDENAFIL; TABEBUIA AVELLANEDAE EXTRACT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; BARK; BRAIN CORTEX; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; IMMOBILITY; LOCOMOTION; MOUSE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; TABEBUIA; TABEBUIA AVELLANEDAE;

ANIMALS; ANTIDEPRESSIVE AGENTS; ARGININE; BEHAVIOR, ANIMAL; DEPRESSION; FEMALE; GUANOSINE MONOPHOSPHATE; HINDLIMB SUSPENSION; LOCOMOTION; MICE; MICE, INBRED STRAINS; NITRIC OXIDE; PHYTOTHERAPY; PLANT EXTRACTS; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION; TABEBUIA;

EID: 84887863944     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2012.0276     Document Type: Article

References (56)

1. Nestler EJ, Barrot M, DiLeone RJ, et al.: Neurobiology of depression. Neuron 2002;34:13-25.
2. Holtzheimer PE, Numeroff CB: Advances in the treatment of depression. NeuroRx 2006;3:42-56.
3. Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-1504.
4. Morilak DA, Frazer A: Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int J Neuropsychopharmacol 2007;7:193-218.
5. Jones K: Pau D'Arco: Immune Power from the Rain Forest. Healing Arts Press, Rochester, 1995.
6. Gómez Castellanos JR, Prieto JM, Heinrich M: Red Lapacho (Tabebuia impetiginosa)-a global ethnopharmacological commodity? J Ethnopharmacol 2009;121:1-13.
7. Lüebeck W: The Healing Power of Pau d'Arco. Lotus Press, United States, 1999.
8. Pereira IT, Burci LM, da Silva LM, et al.: Antiulcer effect of bark extract of Tabebuia avellanedae: activation of cell proliferation in gastric mucosa during the healing process. Phytother Res 2013;27:1067-1073.
9. Twardowschy A, Freitas CS, Baggio CH, et al.: Antiulcerogenic activity of bark extract of Tabebuia avellanedae, Lorentz ex Griseb. J Ethnopharmacol 2008;118:455-459.
10. Freitas AE, Budni J, Lobato KR, et al.: Antidepressant-like action of the ethanolic extract from Tabebuia avellanedae in mice: evidence for the involvement of the monoaminergic system. Prog Neuropsychopharmacol Biol Psychiatry 2010;34: 335-343.
11. Steru L, Chermat R, Thierry B, et al.: The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985;85:367-370-45.
12. Freitas AE, Machado DG, Budni J, et al.: Antidepressant-like action of the bark ethanolic extract from Tabebuia avellanedae in the olfactory bulbectomized mice. J Ethnopharmacol 2013;145:737-45.
13. Skolnick P: Antidepressants for the new millennium. Eur J Pharmacol 1999;375:31-40.
14. Harkin AJ, Bruce KH, Craft B, et al.: Nitric oxide synthase inhibitors have antidepressant-like properties in mice.1. Acute treatments are active in the forced swim test. Eur J Pharmacol 1999;372:207-313.
15. Nowak G, Trullas R, Layer RT, et al.: Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J Pharmacol Exp Ther 1993;265:1380-1386.
16. Bobula B, Tokarski K, Hess G: Repeated administration of antidepressants decreases field potentials in rat frontal cortex. Neuroscience 2003;120:765-769.
17. Popik P, Wróbel M, Nowak G: Chronic treatment with antidepressants affects glycine/NMDA receptor function: Behavioral evidence. Neuropharmacology 2000;39:2278-2287.
18. Krass M, Wegener G, Vasar E, et al.: The antidepressant action of imipramine and venlafaxine involves suppression of nitric oxide synthesis. Behav Brain Res 2011;218:57-63.
19. Zomkowski AD, Engel D, Gabilan NH, et al.: Involvement of NMDA receptors and L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effects of escitalopram in the forced swimming test. Eur Neuropsychopharmacol 2010;20:793-801.
20. Szasz BK, Mike A, Karoly R, et al.: Direct inhibitory effect of fluoxetine on N-methyl-D-aspartate receptors in the central nervous system. Biol Psychiatry 2007;62:1303-1309.
21. Trullas R, Skolnick P: Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990;185:1-10.
22. Papp M, Moryl E: Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur J Pharmacol 1994;263:1-7.
23. Rosa AO, Lin J, Calixto JB, et al.: Involvement of NMDA receptors and L-arginine-nitric oxide pathway in the antidepressantlike effects of zinc in mice. Behav Brain Res 2003;144:87-93.
24. Moncada S, Palmer RM, Higgs EA: Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication. Biochem Pharmacol 1989;38:1709-1715.
25. Da Silva GD, Matteussi AS, dos Santos AR, et al.: Evidence for dual effects of nitric oxide in the forced swimming test and in the tail suspension test in mice. Neuroreport 2000;11:3699-3702.
26. Rogóz Z, Skuza G, Maj J, et al.: Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology 2002;42:1024-1030.
27. Pruus K, Rudissaar R, Allikmets L, et al.: The effect of the NMDA receptor antagonist dizocilpine on behavioral manifestations of serotonin and adrenergic antidepressants in rats. Methods Find Exp Clin Pharmacol 2010;32:123-128.
28. Brocardo PdeS, Budni J, Lobato KR, et al.: Antidepressant-like effect of folic acid: involvement of NMDA receptors and L-arginine-nitric oxide-cyclic guanosine monophosphate pathway. Eur J Pharmacol 2008;598:37-42.
29. Bettio LE, Cunha MP, Budni J, et al.: Guanosine produces an antidepressant-like effect through the modulation of NMDA receptors, nitric oxide-cGMP and PI3K/mTOR pathways. Behav Brain Res 2012;234:137-148.
30. Moretti M, Budni J, Ribeiro CM, et al.: Involvement of different types of potassium channels in the antidepressant-like effect of ascorbic acid in the mouse tail suspension test. Eur J Pharmacol 2012;687:21-27.
31. Mantovani M, Pértile R, Calixto JB, et al.: Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: evidence for involvement of N-methyl-D-aspartate receptors and the L-arginine-nitric oxide pathway. Neurosci Lett 2003;343:1-4.
32. Hevel JM, Marletta MA: Nitric-oxide synthase assays. Methods Enzymol 1994;233:250-258.
33. Binfaré RW, Rosa AO, Lobato KR, et al.: Ascorbic acid administration produces an antidepressant-like effect: evidence for the involvement of monoaminergic neurotransmission. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:530-540.
34. Machado DG, Bettio LE, Cunha MP, et al.: Antidepressant-like effect of the extract of Rosmarinus officinalis in mice: involvement of the monoaminergic system monoaminergic system. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:642-650.
35. Rodrigues AL, Rocha JB, Mello CF, et al.: Effect of perinatal lead exposure on rat behavior in open-field and two-way avoidance tasks. Pharmacol Toxicol 1996;79:150-156.
36. Sánchez-Maldonado AF, Schieber A, Gänzle MG: Structurefunction relationships of the antibacterial activity of phenolic acids and their metabolism by lactic acid bacteria. J Appl Microbiol 2011;111:1176-1184.
37. Singh N, Jabeen T, Pal A, et al.: Crystal structures of the complexes of a group IIA phospholipase A2 with two natural antiinflammatory agents, anisic acid, and atropine reveal a similar mode of binding. Proteins 2006;64:89-100.
38. Saravanakumar M, Raja B: Veratric acid, a phenolic acid attenuates blood pressure and oxidative stress in L-NAME induced hypertensive rats. Eur J Pharmacol 2011;671:87-94.
39. Simic A, Manojlovic D, Segan D, et al.: Electrochemical behavior and antioxidant and prooxidant activity of natural phenolics. Molecules 2007;12:2327-2340.
40. Takeda H, Tsuji M, Inazu M, et al.: Rosmarinic acid and caffeic acid produce antidepressive-like effect in the forced swimming test in mice. Eur J Pharmacol 2002;449:261-267.
41. Takeda H, Tsuji M, Miyamoto J, et al.: Caffeic acid produces antidepressive- and/or anxiolytic-like effects through indirect modulation of the alpha 1A-adrenoceptor system in mice. Neuroreport 2003;14:1067-1070.
42. Takeda H, Tsuji M, Yamada T, et al.: Caffeic acid attenuates the decrease in cortical BDNF mRNA expression induced by exposure to forced swimming stress in mice. Eur J Pharmacol 2006;534:115-121.
43. Dzitoyeva S, Imbesi M, Uz T, et al.: Caffeic acid attenuates the decrease of cortical BDNF transcript IV mRNA induced by swim stress in wild-type but not in 5-lipoxygenase-deficient mice. J Neural Transm 2008;115:823-827.
44. Cryan JF, Mombereau C, Vassout A: The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005;29:571-625.
45. Lara N, Archer SL, Baker GB, et al.: Paroxetine-induced increase in metabolic end products of nitric oxide. J Clin Psychopharmacol 2003;23:641-645.
46. Wong ML, Licinio J: Research and treatment approaches to depression. Nat Rev Neurosci 2001;2:343-351.
47. Sanacora G, Zarate CA, Krystal JH, et al.: Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008;7:426-437.
48. Paul IA, Nowak G, Layer RT, et al.: Adaptation of the N-methyl- D-aspartate receptor complex following chronic antidepressant treatments. J Pharmacol Exp Ther 1994;269:95-102.
49. Skolnick P, Popik P, Trullas R: Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 2009;30:563-569.
50. Harkin A, Connor TJ, Burns MP, et al.: Nitric oxide synthase inhibitors augment the effects of serotonin reuptake inhibitors in the forced swimming test. Eur Neuropsychopharmacol 2004;14: 274-281.
51. Chrapko WE, Jurasz P, Radomski MW, et al.: Decreased platelet nitric oxide synthase activity and plasma nitric metabolites in major depressive disorder. Biol Psychiatry 2004;56:129-134.
52. Oliveira RM, Guimarães FS, Deakin JF: Expression of neuronal nitric oxide synthase in the hippocampal formation in affective disorders. Braz J Med Biol Res 2008;41:333-341.
53. Naseem KM: The role of nitric oxide in cardiovascular diseases. Mol Aspects Med 2005;26:33-65.
54. Zomkowski AD, Engel D, Cunha MP, et al.: The role of the NMDA receptors and L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of duloxetine in the forced swimming test. Pharmacol Biochem Behav 2012;103:408-417.
55. Jesse CR, Wilhelm EA, Bortolatto CF, et al.: Involvement of L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of bis selenide in the mouse tail suspension test. Eur J Pharmacol 2010;635:135-141.
56. Bender AT, Beavo JA: Specific localized expression of cGMP PDEs in Purkinje neurons and macrophages. Neurochem Int 2004;45:853-857.